J. Rossouw, G. Anderson, and R. Prentice, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial, JAMA, vol.288, pp.321-354, 2002.

R. Chlebowski, S. Hendrix, and R. Langer, Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women, JAMA, vol.289, issue.24, pp.3243-53, 2003.
DOI : 10.1001/jama.289.24.3243

V. Beral, Breast cancer and hormone-replacement therapy: the Million Women Study, The Lancet, vol.362, issue.9392, pp.419-446, 2003.
DOI : 10.1016/S0140-6736(03)14596-5

O. Johnell and J. Kanis, An estimate of the worldwide prevalence, mortality and disability associated with hip fracture, Osteoporosis International, vol.13, issue.11, pp.897-902, 2004.
DOI : 10.1007/s00198-004-1627-0

E. Barrett-connor, Fortnightly review: Hormone replacement therapy, BMJ, vol.317, issue.7156, pp.457-61, 1998.
DOI : 10.1136/bmj.317.7156.457

S. Hulley, D. Grady, and T. Bush, Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women, JAMA, vol.280, issue.7, pp.605-618, 1998.
DOI : 10.1001/jama.280.7.605

D. Grady, D. Herrington, and V. Bittner, Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy, JAMA, vol.288, issue.1, pp.49-57, 2002.
DOI : 10.1001/jama.288.1.49

J. Manson, J. Hsia, and K. Johnson, Estrogen plus Progestin and the Risk of Coronary Heart Disease, New England Journal of Medicine, vol.349, issue.6, pp.523-557, 2003.
DOI : 10.1056/NEJMoa030808

J. Hsia, R. Langer, and J. Manson, Conjugated Equine Estrogens and Coronary Heart Disease, Archives of Internal Medicine, vol.166, issue.3, pp.357-65, 2006.
DOI : 10.1001/archinte.166.3.357

F. Grodstein, T. Clarkson, and J. Manson, Understanding the Divergent Data on Postmenopausal Hormone Therapy, New England Journal of Medicine, vol.348, issue.7, pp.645-50, 2003.
DOI : 10.1056/NEJMsb022365

W. Ray, Evaluating Medication Effects Outside of Clinical Trials: New-User Designs, American Journal of Epidemiology, vol.158, issue.9, pp.915-935, 2003.
DOI : 10.1093/aje/kwg231

L. Phillips and R. Langer, Postmenopausal hormone therapy: Critical reappraisal and a unified hypothesis, Fertility and Sterility, vol.83, issue.3, pp.558-66, 2005.
DOI : 10.1016/j.fertnstert.2004.11.012

E. Banks and K. Canfell, Invited Commentary: Hormone Therapy Risks and Benefits--The Women's Health Initiative Findings and the Postmenopausal Estrogen Timing Hypothesis, American Journal of Epidemiology, vol.170, issue.1, pp.24-28, 2009.
DOI : 10.1093/aje/kwp113

G. Sare, L. Gray, and P. Bath, Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis, European Heart Journal, vol.29, issue.16, pp.2031-2072, 2008.
DOI : 10.1093/eurheartj/ehn299

C. Varas-lorenzo, L. Garcia-rodriguez, S. Perez-gutthann, and A. Duque-oliart, Hormone Replacement Therapy and Incidence of Acute Myocardial Infarction : A Population-Based Nested Case-Control Study, Circulation, vol.101, issue.22, pp.2572-78, 2000.
DOI : 10.1161/01.CIR.101.22.2572

C. De-vries, S. Bromley, and R. Farmer, Myocardial infarction risk and hormone replacement: Differences between products, Maturitas, vol.53, issue.3, pp.343-50, 2006.
DOI : 10.1016/j.maturitas.2005.06.004

C. Chilvers, R. Knibb, S. Armstrong, K. Woods, and R. Logan, Post menopausal hormone replacement therapy and risk of acute myocardial infarction ??? a case control study of women in the East Midlands, UK, European Heart Journal, vol.24, issue.24, pp.2197-205, 2003.
DOI : 10.1016/j.ehj.2003.09.019

G. Corrao, A. Zambon, and F. Nicotra, Persistence with oral and transdermal hormone replacement therapy and hospitalisation for cardiovascular outcomes, Maturitas, vol.57, issue.3, pp.315-339, 2007.
DOI : 10.1016/j.maturitas.2007.03.001

E. Lokkegaard, A. Andreasen, R. Jacobsen, L. Nielsen, C. Agger et al., Hormone therapy and risk of myocardial infarction: a national register study, European Heart Journal, vol.29, issue.21, pp.2660-2668, 2008.
DOI : 10.1093/eurheartj/ehn408

J. Hippisley-cox, M. Pringle, N. Crown, and C. Coupland, A case-control study on the effect of hormone replacement therapy on ischaemic heart disease, Br J Gen Pract, vol.53, pp.191-96, 2003.

P. Bath and L. Gray, Association between hormone replacement therapy and subsequent stroke: a meta-analysis, BMJ, vol.330, issue.7487, p.342, 2005.
DOI : 10.1136/bmj.38331.655347.8F

H. Nelson, L. Humphrey, P. Nygren, S. Teutsch, and J. Allan, Postmenopausal Hormone Replacement Therapy, JAMA, vol.288, issue.7, pp.872-81, 2002.
DOI : 10.1001/jama.288.7.872

A. Arana, C. Varas, A. Gonzalez-perez, L. Gutierrez, L. Bjerrum et al., Hormone therapy and cerebrovascular events, Menopause, vol.13, issue.5, pp.730-736, 2006.
DOI : 10.1097/01.gme.0000233494.28335.71

F. Grodstein, J. Manson, M. Stampfer, and K. Rexrode, Postmenopausal Hormone Therapy and Stroke, Archives of Internal Medicine, vol.168, issue.8, pp.861-66, 2008.
DOI : 10.1001/archinte.168.8.861

C. Renoux, S. Dell-'aniello, E. Garbe, and S. Suissa, Hormone replacement therapy use and the risk of stroke, Maturitas, vol.61, issue.4, pp.305-314, 2008.
DOI : 10.1016/j.maturitas.2008.09.020

R. Prentice, R. Langer, and M. Stefanick, Combined Postmenopausal Hormone Therapy and Cardiovascular Disease: Toward Resolving the Discrepancy between Observational Studies and the Women's Health Initiative Clinical Trial, American Journal of Epidemiology, vol.162, issue.5, pp.404-418, 2005.
DOI : 10.1093/aje/kwi223

R. Lemaitre, N. Weiss, and N. Smith, Esterified Estrogen and Conjugated Equine Estrogen and the Risk of Incident Myocardial Infarction and Stroke, Archives of Internal Medicine, vol.166, issue.4, pp.399-404, 2006.
DOI : 10.1001/archinte.166.4.399

M. Canonico, G. Plu-bureau, G. Lowe, and P. Scarabin, Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis, BMJ, vol.336, issue.7655, pp.1227-1258, 2008.
DOI : 10.1136/bmj.39555.441944.BE
URL : https://hal.archives-ouvertes.fr/inserm-01142884

E. Daly, M. Vessey, M. Hawkins, J. Carson, P. Gough et al., Risk of venous thromboembolism in users of hormone replacement therapy, The Lancet, vol.348, issue.9033, pp.977-80, 1996.
DOI : 10.1016/S0140-6736(96)07113-9

G. Perez, G. Rodriguez, L. Castellsague, J. Duque, and O. , Hormone replacement therapy and risk of venous thromboembolism: population based case-control study, BMJ, vol.314, pp.796-800, 1997.

E. Hoibraaten, M. Abdelnoor, and P. Sandset, Hormone replacement therapy with estradiol and risk of venous thromboembolism--a population-based case-control study, Thromb Haemost, vol.82, pp.1218-1239, 1999.

C. Varas-lorenzo, L. Garcia-rodriguez, C. Cattaruzzi, M. Troncon, L. Agostinis et al., Hormone Replacement Therapy and the Risk of Hospitalization for Venous Thromboembolism: A Population-based Study in Southern Europe, American Journal of Epidemiology, vol.147, issue.4, pp.387-90, 1998.
DOI : 10.1093/oxfordjournals.aje.a009461

M. Canonico, E. Oger, and . Plu-bureau, Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study, Circulation, vol.115, issue.7, pp.840-845, 2007.
DOI : 10.1161/CIRCULATIONAHA.106.642280
URL : https://hal.archives-ouvertes.fr/hal-00688234

M. Canonico, A. Fournier, and L. Carcaillon, Postmenopausal Hormone Therapy and Risk of Idiopathic Venous Thromboembolism: Results From the E3N Cohort Study, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.30, issue.2, pp.340-345, 2010.
DOI : 10.1161/ATVBAHA.109.196022
URL : https://hal.archives-ouvertes.fr/inserm-01142846

V. Cogliano, Y. Grosse, R. Baan, K. Straif, B. Secretan et al., Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment, The Lancet Oncology, vol.6, issue.8, pp.552-53, 2005.
DOI : 10.1016/S1470-2045(05)70273-4

N. Shah, J. Borenstein, and R. Dubois, Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis, Menopause, vol.12, issue.6, pp.668-78, 2005.
DOI : 10.1097/01.gme.0000184221.63459.e1

J. Collins, J. Blake, and P. Crosignani, Breast cancer risk with postmenopausal hormonal treatment, Human Reproduction Update, vol.11, issue.6, pp.545-60, 2005.
DOI : 10.1093/humupd/dmi028

R. Chlebowski, L. Kuller, and R. Prentice, Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women, New England Journal of Medicine, vol.360, issue.6, pp.573-87, 2009.
DOI : 10.1056/NEJMoa0807684

V. Ringa and A. Fournier, Did the decrease in use of menopausal hormone therapy induce a decrease in the incidence of breast cancer in France (and elsewhere)?, Revue d'??pid??miologie et de Sant?? Publique, vol.56, issue.5, pp.297-301, 2008.
DOI : 10.1016/j.respe.2008.09.001

M. Stefanick, G. Anderson, and K. Margolis, Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy, JAMA, vol.295, issue.14, pp.1647-57, 2006.
DOI : 10.1001/jama.295.14.1647

H. Lyytinen, E. Pukkala, and O. Ylikorkala, Breast Cancer Risk in Postmenopausal Women Using Estrogen-Only Therapy, Obstetrics & Gynecology, vol.108, issue.6, pp.1354-60, 2006.
DOI : 10.1097/01.AOG.0000241091.86268.6e

H. Lyytinen, E. Pukkala, and O. Ylikorkala, Breast Cancer Risk in Postmenopausal Women Using Estradiol???Progestogen Therapy, Obstetrics & Gynecology, vol.113, issue.1, pp.65-73, 2009.
DOI : 10.1097/AOG.0b013e31818e8cd6

H. Lyytinen, T. Dyba, E. Pukkala, Y. , and O. , Do the dose or route of administration of norethisterone acetate as a part of hormone therapy play a role in risk of breast cancer: National-wide case-control study from Finland, International Journal of Cancer, vol.184, issue.1, 2010.
DOI : 10.1002/ijc.24996

A. Fournier, F. Berrino, E. Riboli, V. Avenel, and F. Clavel-chapelon, Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort, International Journal of Cancer, vol.158, issue.3, pp.448-54, 2005.
DOI : 10.1002/ijc.20710
URL : https://hal.archives-ouvertes.fr/inserm-00129104

A. Fournier, F. Berrino, and F. Clavel-chapelon, Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study, Breast Cancer Research and Treatment, vol.95, issue.1, pp.103-114, 2008.
DOI : 10.1007/s10549-007-9523-x
URL : https://hal.archives-ouvertes.fr/inserm-00201813

L. Opatrny, S. Dell-'aniello, S. Assouline, and S. Suissa, Hormone replacement therapy use and variations in the risk of breast cancer, BJOG: An International Journal of Obstetrics & Gynaecology, vol.48, issue.2, pp.169-75, 2008.
DOI : 10.1111/j.1471-0528.2007.01520.x

G. Corrao, A. Zambon, and V. Conti, Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation, Annals of Oncology, vol.19, issue.1, pp.150-155, 2008.
DOI : 10.1093/annonc/mdm404

S. Lee, R. Ross, and M. Pike, An overview of menopausal oestrogen???progestin hormone therapy and breast cancer risk, British Journal of Cancer, vol.151, issue.11, pp.2049-58, 2005.
DOI : 10.1016/S0029-7844(02)02502-4

S. Salpeter, J. Walsh, T. Ormiston, E. Greyber, N. Buckley et al., Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women, Diabetes, Obesity and Metabolism, vol.35, issue.5, pp.538-54, 2006.
DOI : 10.1001/jama.279.18.1445

J. Manson, E. Rimm, and G. Colditz, A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus, Annals of Epidemiology, vol.2, issue.5, pp.665-73, 1992.
DOI : 10.1016/1047-2797(92)90011-E

B. Lauzon-guillain, A. Fournier, and A. Fabre, Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle G??n??rale de l???Education Nationale (E3N) cohort, Diabetologia, vol.102, issue.137, pp.2092-100, 2009.
DOI : 10.1007/s00125-009-1456-y

L. Gabal, D. Goodman-gruen, and E. Barrett-connor, The effect of postmenopausal estrogen therapy on the risk of non-insulin-dependent diabetes mellitus., American Journal of Public Health, vol.87, issue.3, pp.443-488, 1997.
DOI : 10.2105/AJPH.87.3.443

Y. Zhang, B. Howard, and L. Cowan, The Effect of Estrogen Use on Levels of Glucose and Insulin and the Risk of Type 2 Diabetes in American Indian Postmenopausal Women : The Strong Heart Study, Diabetes Care, vol.25, issue.3, pp.500-504, 2002.
DOI : 10.2337/diacare.25.3.500

R. Rossi, G. Origliani, and M. Modena, Transdermal 17-??-Estradiol and Risk of Developing Type 2 Diabetes in a Population of Healthy, Nonobese Postmenopausal Women, Diabetes Care, vol.27, issue.3, pp.645-694, 2004.
DOI : 10.2337/diacare.27.3.645

F. Grodstein, P. Newcomb, and M. Stampfer, Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis, Climacteric, vol.2, issue.3, pp.574-82, 1999.
DOI : 10.3109/13697139909038076

P. Campbell, P. Newcomb, S. Gallinger, M. Cotterchio, and J. Mclaughlin, Exogenous hormones and colorectal cancer risk in Canada: associations stratified by clinically defined familial risk of cancer, Cancer Causes & Control, vol.137, issue.7, pp.723-756, 2007.
DOI : 10.1007/s10552-007-9015-7

J. Johnson, J. Lacey, J. Lazovich, and D. , Menopausal Hormone Therapy and Risk of Colorectal Cancer, Cancer Epidemiology Biomarkers & Prevention, vol.18, issue.1, pp.196-203, 2009.
DOI : 10.1158/1055-9965.EPI-08-0596

G. Rennert, H. Rennert, M. Pinchev, O. Lavie, and S. Gruber, Use of Hormone Replacement Therapy and the Risk of Colorectal Cancer, Journal of Clinical Oncology, vol.27, issue.27, pp.4542-4589, 2009.
DOI : 10.1200/JCO.2009.22.0764

P. Newcomb, Y. Zheng, and V. Chia, Estrogen Plus Progestin Use, Microsatellite Instability, and the Risk of Colorectal Cancer in Women, Cancer Research, vol.67, issue.15, pp.7534-7573, 2007.
DOI : 10.1158/0008-5472.CAN-06-4275

J. Hildebrand, E. Jacobs, and P. Campbell, Colorectal Cancer Incidence and Postmenopausal Hormone Use by Type, Recency, and Duration in Cancer Prevention Study II, Cancer Epidemiology Biomarkers & Prevention, vol.18, issue.11, pp.2835-2876, 2009.
DOI : 10.1158/1055-9965.EPI-09-0596

G. Kabat, A. Miller, and T. Rohan, Oral contraceptive use, hormone replacement therapy, reproductive history and risk of colorectal cancer in women, International Journal of Cancer, vol.5, issue.3, pp.643-689, 2008.
DOI : 10.1002/ijc.23079

C. Ritenbaugh, J. Stanford, and L. Wu, Conjugated Equine Estrogens and Colorectal Cancer Incidence and Survival: The Women's Health Initiative Randomized Clinical Trial, Cancer Epidemiology Biomarkers & Prevention, vol.17, issue.10, pp.2609-2627, 2008.
DOI : 10.1158/1055-9965.EPI-08-0385

R. Chlebowski, J. Wactawski-wende, and C. Ritenbaugh, Estrogen plus Progestin and Colorectal Cancer in Postmenopausal Women, New England Journal of Medicine, vol.350, issue.10, pp.991-1004, 2004.
DOI : 10.1056/NEJMoa032071

I. Csizmadi, J. Collet, A. Benedetti, J. Boivin, and J. Hanley, The effects of transdermal and oral oestrogen replacement therapy on colorectal cancer risk in postmenopausal women, British Journal of Cancer, vol.90, issue.1, pp.76-81, 2004.
DOI : 10.1038/sj.bjc.6601438

M. Hoffmeister, E. Raum, A. Krtschil, J. Chang-claude, and H. Brenner, No Evidence for Variation in Colorectal Cancer Risk Associated With Different Types of Postmenopausal Hormone Therapy, Clinical Pharmacology & Therapeutics, vol.9, issue.4, pp.416-440, 2009.
DOI : 10.1002/ijc.23655

J. Dinger, L. Heinemann, S. Mohner, . Thai-dm, and A. Assmann, Colon cancer risk and different HRT formulations: a case-control study, BMC Cancer, vol.24, issue.1, p.76, 2007.
DOI : 10.1385/ENDO:24:3:203

J. Cauley, J. Robbins, and Z. Chen, Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density<SUBTITLE>The Women's Health Initiative Randomized Trial</SUBTITLE>, JAMA, vol.290, issue.13, pp.1729-1767, 2003.
DOI : 10.1001/jama.290.13.1729

R. Jackson, J. Wactawski-wende, and A. Lacroix, Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial, Journal of Bone and Mineral Research, vol.22, issue.6, pp.817-845, 2006.
DOI : 10.1359/jbmr.060312

S. Hulley, C. Furberg, and E. Barrett-connor, Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy, JAMA, vol.288, issue.1, pp.58-66, 2002.
DOI : 10.1001/jama.288.1.58

D. Torgerson and S. Bell-syer, Hormone Replacement Therapy and Prevention of Nonvertebral Fractures, JAMA, vol.285, issue.22, pp.2891-97, 2001.
DOI : 10.1001/jama.285.22.2891

E. Banks, V. Beral, G. Reeves, A. Balkwill, and I. Barnes, Fracture Incidence in Relation to the Pattern of Use of Hormone Therapy in Postmenopausal Women, JAMA, vol.291, issue.18, pp.2212-2232, 2004.
DOI : 10.1001/jama.291.18.2212

P. Vestergaard, L. Rejnmark, and L. Mosekilde, Fracture reducing potential of hormone replacement therapy on a population level, Maturitas, vol.54, issue.3, pp.285-93, 2006.
DOI : 10.1016/j.maturitas.2005.12.004

M. Weiner, K. Barnhart, D. Xie, and R. Tannen, Hormone therapy and coronary heart disease in young women, Menopause, vol.PAP, pp.86-93, 2008.
DOI : 10.1097/gme.0b013e3180413e45

K. Michaelsson, J. Baron, and B. Farahmand, Hormone replacement therapy and risk of hip fracture: population based case-control study, BMJ, vol.316, issue.7148, pp.1858-63, 1998.
DOI : 10.1136/bmj.316.7148.1858